The Therapeutic Goods Administration has announced that it will not use 4-letter suffixes in naming biologic and biosimilar medicines (as the FDA currently requires).
Therapeutic Goods Administration (TGA) in Australia has announced that it will not use 4-letter suffixes in naming biologic and biosimilar medicines as the FDA currently requires.
The decision comes after several years of consideration and evaluation, and the adoption of different global approaches. When the time came to make a decision, the TGA considered 4 options:
TGA heard suggestions and concerns from various stakeholders in evaluating its decision. According to TGA, this decision is supported by most stakeholders. TAG’s position includes a future possible move toward adopting the EU’s barcode system, which incorporates the product code, national identification number, batch number, and expiry date.
In addition to the updated naming practice, the government also announced that its decision to strengthen AE reporting will include making the products’ brand name as well as non-proprietary name a mandatory field when reporting an AE.
The International Generic and Biosimilar medicines Association (IGBA) announced its support of the Australian Government’s decision to maintain the existing mandate for naming biologic and biosimilar medicines.
The government’s decision aligns with that of the European Union, which has approved the largest number of biosimilar medicines worldwide. The decision also aligns with the World Health Organization’s (WHO) approach to nomenclature.
The decision stands in contrast to the United States’ approach, however, whereby all biologics and biosimilars must have a 4-letter suffix, devoid of meaning, added to the end of newly approved biologics’ and biosimilars’ nonproprietary names. The first implementation of the FDA’s mandate to apply the suffix to newly approved innovator drugs came in November 2017 with the FDA approval of Roche’s Hemlibra (emicizumab-kxwh).
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.